If you haven’t been living under a rock for the past few years, you have undoubtedly heard about cannabidiol (CBD). The cannabis extract has been having quite the magnificent run, with the CBD industry expected to be worth $20 billion by 2024. This growth is due to the compound’s insane potency and versatility as a medicine, with users saying CBD gave them relief from a variety of diseases ranging from high blood pressure to seizures in rare childhood epilepsies. Chronic pain relief is by far the most common issue CBD users seek to address, and a new study has produced further evidence that CBD can be useful as a pain reliever.
The study led by Dr. Alex Capano, Chief Science Officer of Ecofibre’s Ananda Health business in the United States, was looking to prove whether using CBD would reduce opioid use in the treatment of chronic pain. Ninety-seven chronic pain patients who had been using opioids for pain relief, some for decades, took part in the eight-week study. They were each provided with bottles containing 60 hemp-derived CBD soft gels (15 mg) at the start of the study, in week four, and week eight. 53 percent reported that they reduced or completely stopped opioid use, and 94 percent reported improved quality of life, especially improvements in sleep, pain, and mood. Although a small number experienced side effects, there was nothing significant.
Dr. Capano says that most participants used a low dose of 30mg of CBD per day, unlike other studies on CBD that have tested large doses of up to ten and twenty times that amount. “Lower doses of CBD mean reduced risk of side effects and improved outcomes,” he says. The study’s findings were consistent with emerging literature on the topic, which has concluded that CBD is an effective analgesic and one that helps reduce barriers to opioid reduction, such as physiological withdrawal symptoms.
This isn’t the first time research on the efficacy of CBD as an alternative to opioids has been conducted. A previous study found that CBD reduced cravings and anxiety caused by opioid dependence.
Although Dr. Capano’s study indicates that using CBD-rich extracts can help chronic pain patients to reduce or completely eliminate opioid use and enjoy an improved quality of life, it should be noted that the study was limited by a lack of randomized, placebo-controlled design, had a short duration, lacked a control group and used a small sample size.
Nevertheless, analysts are convinced that these results give credence to what the CBD industry, including players like Willow Biosciences Inc. (CSE: WLLW) and VPR Brands LP (OTCQB: VPRB), have always believed that CBD can provide a viable solution to the opioid crisis in the nation.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
